ClinicalTrials.gg
WithdrawnNCT02584777Updated May 5, 2021

A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

A Phase 2 interventional study of Pacritinib in Primary Myelofibrosis, sponsored by Baxalta now part of Shire. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-05.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Enrollment
17th of 18
0 · median 35
Started
2015
with 2 others
Phase 2
8 of 18
4 open now
Registered
7th of 18
by date
Lead sponsor
1 of 18
Baxalta now part of Shire

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 17th largest by enrollment, is one of 3 that started in 2015, is one of 8 in phase 2, and was the 7th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

To evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of pacritinib in Asian subjects with myelofibrosis (MF), which includes primary MF (PMF), post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF).

03

Conditions studied

  • Primary Myelofibrosis

Browse trials for

Keywords

  • Post-essential thrombocythemia myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Intermediate-1, intermediate-2, or high-risk PMF, PPV-MF or PET-MF as based on The Dynamic International Prognostic Scoring System (DIPSS) criteria
  2. Palpable splenomegaly ≥5 cm below the LCM in midclavicular line by physical examination
  3. TSS ≥13 on the MPN-SAF TSS 2.0, not including the inactivity question, based on a single assessment during screening visit
  4. Age ≥18 years old at the time of screening (or minimum age of legal consent consistent with local regulations, if minimum is >18 years of age)
  5. performance status 0 to 3
  6. Peripheral blast count \<10%
  7. >500/μL
  8. Participants who are or RBC transfusion dependent are eligible
  9. Adequate liver and renal function, defined by liver transaminases (/serum glutamic oxaloacetic transaminase [SOOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]) ≤3 × ([ULN], AST/ALT ≤5 × ULN if transaminase elevation is related to MF), direct ≤4 × ULN, and creatinine ≤2.5 mg/dL
  10. At least 6 months from prior splenic irradiation
  11. At least 12 months from prior 32P therapy
  12. At least 1 week since prior treatment (most recent dose) with a potent inhibitor or inducer
  13. At least 4 weeks since any experimental treatment for PMF, PPV-MF, or PET-MF
  14. At least 2 weeks since any treatment for PMF, PPV-MF, or PET-MF
  15. If fertile, both males and females must agree to use effective .
  16. Able to understand and willing to complete symptom assessments using a patient-reported outcomes instrument and comply with treatment and study procedures of the protocol
  17. Able to understand and willing to sign the form (ICF)
  18. Participant is willing and able to comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  1. Any GI or metabolic condition that could interfere with absorption of oral medication
  2. \<6 months
  3. Prior treatment with a JAK2 inhibitor
  4. Completed , or are eligible for and willing to complete ASCT
  5. History of splenectomy or planning to undergo splenectomy
  6. Uncontrolled intercurrent illness, including but not limited to ongoing active infection, or psychiatric illness, or social situation that, in the judgment of the treating physician, would limit compliance with study requirements
  7. Other within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ confined, or treated non- prostate cancer with negative prostate specific antigen, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma
  8. Inflammatory or chronic functional bowel disorder, such as Crohn's disease, inflammatory bowel disease, chronic diarrhea, or constipation
  9. Clinically symptomatic and uncontrolled cardiovascular disease
  10. History of any of the following within 6 months prior to first dose of pacritinib: myocardial infarction, severe/unstable angina, or symptomatic congestive heart failure
  11. Class II, III, or IV congestive heart failure
  12. Participants with (version 4.03) Grade 2 cardiac arrhythmias may be considered for inclusion, with the approval of the medical monitor, if the arrhythmias are stable, asymptomatic and unlikely to affect participant safety. Participants will be excluded if they have ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥3, prolongation >450 ms, or other conditions that increase the risk for QT interval prolongation (eg, heart failure, hypokalemia [defined as serum potassium \<3.0 mEq/L that is persistent and to correction], or family history of long QT interval syndrome)
  13. Erythropoietic agent within 28 days prior to first dose of pacritinib
  14. Thrombopoietic agent within 14 days prior to first dose of pacritinib
  15. Known seropositivity for or syphilis, or known active hepatitis A, B or C virus infection
  16. Participant has participated in another clinical study involving an IP or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  17. Participant is a family member or employee of the investigator
  18. If female, participant is pregnant or breastfeeding at the time of enrollment. Even if breastfeeding can be discontinued, the participant should not be enrolled in the study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pacritinib

    Oral administration

    Biological: Pacritinib

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving a ≥35% reduction in spleen volume

    Measured by MRI or CT scan

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Proportion of participants with ≥50% reduction in total symptom score (TSS)

    Measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) TSS 2.0

    Time frame: Baseline to Week 24

  2. Proportion of participants with baseline platelet count <100,000/μL achieving ≥35% reduction in spleen volume

    Measured by MRI or CT scan

    Time frame: Baseline to Week 24

  3. Proportion of participants with baseline platelet count <100,000/μL achieving ≥50% reduction in total symptom score (TSS)

    Time frame: Baseline to Week 24

  4. Proportion of participants with baseline platelet count <50,000/μL achieving ≥35% reduction in spleen volume

    Measured by MRI or CT scan

    Time frame: Baseline to Week 24

  5. Proportion of participants with baseline platelet count <50,000/μL achieving ≥50% reduction in total symptom score (TSS)

    Time frame: Baseline to Week 24

  6. Clinically significant adverse events (AEs)

    Time frame: Throughout the study period of approximately 5 years

  7. Clinically significant changes in laboratory results

    Time frame: Throughout the study period of approximately 5 years

  8. Clinically significant changes in vital signs

    Time frame: Throughout the study period of approximately 5 years

  9. Clinically significant changes in electrocardiograms (ECGs)

    Time frame: Throughout the study period of approximately 5 years

  10. Pacritinib pharmacokinetic (PK) parameter: maximum observed concentration (Cmax)

    Time frame: Baseline; weeks 3, 12 & 24

  11. Pacritinib pharmacokinetic (PK) parameter: Time of maximum observed concentration (Tmax)

    Time frame: Baseline; weeks 3, 12 & 24

  12. Pacritinib pharmacokinetic (PK) parameter: minimum observed concentration (Cmin)

    Time frame: Baseline; weeks 3, 12 & 24

  13. Pacritinib pharmacokinetic (PK) parameter: area under the concentration curve (AUC)

    Time frame: Baseline; weeks 3, 12 & 24

  14. Pacritinib pharmacokinetic (PK) parameter: apparent volume of distribution (V/F)

    Time frame: Baseline; weeks 3, 12 & 24

  15. Pharmacodynamic parameter: Maximum observed effect (Emax)

    Time frame: Baseline; weeks 3, 12 & 24

  16. Pharmacodynamic parameter: time of maximum observed effect (tEmax)

    Time frame: Baseline; weeks 3, 12 & 24

  17. Pharmacodynamic parameter: area under the effect curve (AUEC)

    Time frame: Baseline; weeks 3, 12 & 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Sep 2017, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2015
First posted
Oct 23, 2015
StartActual
Nov 30, 2015
Primary completionActual
Sep 30, 2017
CompletionActual
Aug 31, 2020
Last update
May 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02584777
Collaborators
CTI BioPharma
Responsible party
Sponsor
First posted
Oct 23, 2015
Start date
Nov 30, 2015
Primary completion
Sep 30, 2017
Completion
Aug 31, 2020
Last update
May 5, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion